Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Re-Injection of NX-1207 for BPH
NCT01438775Phase 3Completed
- Sponsor
- Nymox Pharmaceutical
- Start
- Sep 2011
- Primary completion
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fexapotide triflutate in benign prostatic hyperplasia (BPH), sponsored by Nymox Pharmaceutical. Primary endpoint: Safety at 180 days. Started Sep 2011; status: completed.
02
Drugs
fexapotide triflutate
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01438775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01438775.